Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy
References (29)
- et al.
Repetitive highdose therapy with ifosfamide, thiotepa and paclitaxel with blood cell support for metastatic breast cancer: results of Phase I study
Ann Oncol
(1999) - et al.
Comparison of three methods of CD34+ cell enumeration in peripheral blood: dual platform ISHAGE protocol versus single-platform, versus microvolume fluorimetry
Cytotherapy
(2000) - et al.
Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction
Blood
(1997) - et al.
Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage
Blood
(1992) - et al.
Ex vivo hematopoietic progenitor cell expansion
Immunomethods
(1994) - et al.
Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer
Blood
(1996) - et al.
Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-postive cells
Lancet
(1999) - et al.
Repetitive highdose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study
Bone Marrow Transplant
(2000) - et al.
Repetitive highdose therapy with peripheral blood progenitor support for metastatic and locally advanced breast cancer
- et al.
Ex vivo culture of peripheral blood CD34+ cells: effects of hematopoietic growth factors on production of neutrophil precursors
J Hematother
(1997)
Clinical applications of ex vivo expanded cells
Cancer Res Ther Control
Ex vivo expansion of human hemopoietic progenitors with cytokines
Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer
Bone Marrow Transplant
Docetaxel effectively mobilizes peripheral blood CD34+ cells
Bone Marrow Transplant
Cited by (10)
CD34<sup>+</sup> Hematopoietic Progenitor Cell Selection of Bone Marrow Grafts for Autologous Transplantation in Pediatric Patients
2007, Biology of Blood and Marrow TransplantationCitation Excerpt :The specific licensed use of the Isolex® device is for CD34+ selection of hematopoietic stem cells from autologous peripheral blood of patients with malignancies. The majority of published literature has described its use in processing peripheral blood stem cell (PBSC) grafts of patients with breast cancer, multiple myeloma, and lymphoma [2,7-10]. CD34+-selected grafts have reproducibly resulted in acceptable neutrophil and platelet engraftment in these circumstances [1].
Recent Australian experience with hemopoietic stem and progenitor cell expansion
2007, CytotherapyCitation Excerpt :In brief, this study involved three cohorts of three patients with advanced breast cancer who received three repetitive cycles of high-dose therapy (HDT) comprising CY (4 g/m2), thiotepa (300 mg/m2) and paclitaxel (17 mg/m2) and then infusion with either unmanipulated and/or ex vivo-expanded cells. It had previously been demonstrated that this HDT regimen was extremely myelosuppressive [15, 16] and as such provided a ‘window of opportunity’ to test whether transfusion of ex vivo-expanded cells could abrogate the predictably severe cytopenia. In the first cohort (three patients), the first of three HDT cycles was supported by unmanipulated cells infused on day 0, and the second and third cycles were supported with ex vivo-expanded cells and unmanipulated PBPC, both infused on day 0.
Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells
2005, BloodCitation Excerpt :Low-density BM cells were isolated from CB by discontinuous density centrifugation using Ficoll-Hypaque (1.077 g/mL; Pharmacia Biotech, Uppsala, Sweden). A variation of the Dynal bead method for clinical scale selection of cells using the Isolex 300i (Miltenyi Biotech, Bergisch, Germany) was used for isolation of CD34+ cells.30 CB mononuclear cells were incubated with anti-CD34, washed, and exposed to Dynal anti–mouse immunoglobulin G (IgG) beads to rosette CD34+ cells.
Approaches to Hematopoietic Stem Cell Separation and Expansion
2004, Handbook of Stem CellsPeripheral Blood Stem Cells
2004, Handbook of Pediatric Transfusion MedicineCellular Engineering for the Production of New Blood Components
2016, Transfusion Medicine